Leukemia core transcriptional circuitry is a sparsely interconnected hierarchy stabilized by incoherent feed-forward loops.


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
15 Mar 2023
Historique:
pubmed: 31 3 2023
medline: 31 3 2023
entrez: 30 3 2023
Statut: epublish

Résumé

Lineage-defining transcription factors form densely interconnected circuits in chromatin occupancy assays, but the functional significance of these networks remains underexplored. We reconstructed the functional topology of a leukemia cell transcription network from the direct gene-regulatory programs of eight core transcriptional regulators established in pre-steady state assays coupling targeted protein degradation with nascent transcriptomics. The core regulators displayed narrow, largely non-overlapping direct transcriptional programs, forming a sparsely interconnected functional hierarchy stabilized by incoherent feed-forward loops. BET bromodomain and CDK7 inhibitors disrupted the core regulators' direct programs, acting as mixed agonists/antagonists. The network is predictive of dynamic gene expression behaviors in time-resolved assays and clinically relevant pathway activity in patient populations.

Identifiants

pubmed: 36993171
doi: 10.1101/2023.03.13.532438
pmc: PMC10054969
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL155144
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211199
Pays : United States

Auteurs

Taku Harada (T)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Jérémie Kalfon (J)

Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02142, USA.

Monika W Perez (MW)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Kenneth Eagle (K)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.
Ken Eagle Consulting, Houston, TX, 77494, USA.

Flora Dievenich Braes (FD)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Rashad Batley (R)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Yaser Heshmati (Y)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Juliana Xavier Ferrucio (JX)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Jazmin Ewers (J)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Stuti Mehta (S)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Andrew Kossenkov (A)

The Wistar Institute, Philadelphia, PA, 19104, USA.

Jana M Ellegast (JM)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.
Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02142, USA.

Allyson Bowker (A)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Jayamanna Wickramasinghe (J)

The Wistar Institute, Philadelphia, PA, 19104, USA.

Behnam Nabet (B)

Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.

Vikram R Paralkar (VR)

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.

Neekesh V Dharia (NV)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.
Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02142, USA.

Kimberly Stegmaier (K)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.
Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02142, USA.

Stuart H Orkin (SH)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.
Howard Hughes Medical Institute, Boston, MA, 02115, USA.

Maxim Pimkin (M)

Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.
Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 02142, USA.

Classifications MeSH